From the intensity matrix, the probability of progression from any state i to any state j in any time interval t, can be defined as P ij (t).
Transitions between serial states were quantified by two instantaneous progression rates from state 1 to 2 (λ1) and from state 2 to 3 (λ3), and two instantaneous regression rates from state 2 to 1 (λ2) and state 3 to 2 (λ4).
The progression from each state to the next follows a Markov process that assumes that transition depends only on the current state, i.e. the process has no memory.
Developmental progression from ground state pluripotency entails dissolution of a transcription factor circuit that is highly recursive and robust.
In the Diabetes Prevention Program, MET showed the ability to slow the progression from a state of impaired glucose tolerance to T2DM [ 27, 28].
The clinical entity of RF+CVF represents a temporal and clinical progression from the state where only one is present – the key question during this progression being what changes are occurring in peripheral insulin sensitivity and beta-cell function.
Results from the DPP [ 5] and other similar studies demonstrated that changes in lifestyle, such as a proper diet and increased physical activity, play a crucial role in preventing or slowing the progression from a state of IR to a frank diabetes [ 31, 32].
The WT cell cycle was simulated with a period of 31 time-steps, with a complete cycle defined (as in [ 23]) as the progression from the state representing START through the activation of the CYTOKINESIS variable to level 2, and, finally, the return of the value of MASS, after cytokinesis, to one, which initiates the next START.
CNA profiles in CIN CRC are not consistent with the conventional scheme stating a stepwise progression from stage 1 to stage 4. The level and pattern of genetic instability has been found to correlate with disease outcome, as tumors with fractionated gains and losses were of worse prognosis than tumors showing low breakpoint levels.
Disease recurrence was modelled as women's underlying health state progression from a no CIN state to CIN2+ after treatment at a specific annual rate.
